Development of immunoassays to measure tau for blood-based screening of Alzheimer’s disease

Takeaway

  • In an N-terminal assay (NT1), tau levels were elevated in the plasma of Alzheimer’s disease (AD) and AD-mild cognitive impairment (MCI) patients.

Why this matters

  • There is a need for less costly and intrusive, blood-based biomarkers to aid the diagnosis of AD.